In a recent Phase III bipolar disorder trial, our customer set an aggressive timeline to meet an NDA filing window. IQVIA accelerated site identification and patient recruitment to help our customer achieve this milestone.

Learn More

IQVIA Core-Powered Clinical Development. Our CORE-powered approach to clinical development dramatically increases speed and efficiency to help you bring your products to patients faster. • Accelerate site identification by up to 40%. • Increase patient enrollment by up to 30%. • Applied to more than 200 clinical studies.

Proof, not promises.

Learn More

Data based on a recent Phase III bipolar disorder trial. Comparisons based on previous studies in the same indication and geographies conducted by IQVIA. Results may vary due to various factors.